Camtarkibart

卡泰奇拜单抗

Report date: 2026/04/16 20:00:17

Base Information

Drug NameCamtarkibart
Drug Alias Name重组抗IL-4Rα人源化单克隆抗体（三生国建）611611 Q2W611 Q4W611-3SBio +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-4 receptor subunit alpha inhibitors
TargetsInterleukin-4 receptor subunit alpha
Therapy Area/IndicationsPolypsDermatitis, AtopicNasal Polyps +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsPolypsDermatitis, AtopicNasal Polyps +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A